Introduction: We encountered a 6-year-old girl with systemic lupus erythematosus.
Introduction
Fibrinogen is a 340 kDa plasma glycoprotein composed of two sets of three different polypeptide chains (A, B and  [1, 2] , and physiologically functions in blood coagulation, fibrinolysis, wound healing, and angiogenesis [3] . Each chain is coded by the FGA, FGB, FGG genes, respectively, and then synthesized, assembled into a six-chain molecule in hepatocytes, which is expressed as (A, B, )2, and secreted into the blood. The six chains are arranged into three globular regions (a central E region and two distal D regions) connected by linear segments called coiled-coil connectors. The E region contains the N-termini of all chains [3] .
During blood coagulation, thrombin cleaves four short peptides from fibrinogen to form fibrin monomers. In brief, two sets of fibrinopeptide A and fibrinopeptide B are released from the N-termini of the A and B chains, respectively, which exposes the knobs 'A' and knobs 'B'. The fibrin monomers spontaneously polymerize in a two-step fashion [3] . In the first step, the so-called knob 'A', hole 'a', and D-D interactions form half-staggered, double-stranded protofibrils and the second step of polymerization, termed lateral aggregation, occurs. The release of fibrinopeptide B promotes lateral aggregation [4] . The final product is an insoluble fibrin network consisting of multi-stranded, branched fibers [3] . Three clinical manifestations; a tendency towards bleeding (26.1 %), thrombosis (18.6 %), and renal amyloidosis (7.2 %), are also associated with dysfibrinogenemia, whereas 48.2 % of carriers are asymptomatic. The C-domains of the fibrinogen molecule (A chain amino acid sequence 392-610) are folded into a globular structure, interact with the central region of the molecule, and play an important role in enhancing lateral aggregation [6, 7] . Furthermore, several variants have been identified in this domain, namely truncated or albumin-binding forms or pathogenic forms of familial renal amyloidosis [5] .
We recently found a novel heterozygous dysfunctional fibrinogen, in which Ser was substituted for A472Cys in the C-domain, analyzed its molecular characterization, fibrin polymerization, fibrin clot and fiber structure, and clot lysis by tissue-type plasminogen activator (t-PA)-mediated plasminogen activation, and compared these 6 with those of other fibrinogen variants located in the C-domain, which are present as albumin-binding variant fibrinogens.
Materials and methods
This study was approved by the Ethics Review Board of Shinshu University School of Medicine. After informed consent had been obtained from the parents, blood samples were collected for biochemical and genetical analyses.
Patient
The proposita was a 6-year-old girl with systemic lupus erythematosus. Since she was positive for serum anti-cardiolipin-2glycoprotein I antibodies, she had taken warfarin to prevent the thrombosis associated with anti-phospholipid syndrome. Before being diagnosed, her plasma fibrinogen concentration was continuously lower than the lower-level of reference intervals without bleeding or a thrombotic tendency. Her mother had a similar plasma fibrinogen concentration to the proposita, but had no history of bleeding or a thrombotic tendency, and her father's plasma fibrinogen concentration was normal. (Sekisui Medical Co., Tokyo, Japan). The immunological fibrinogen concentration was determined using anti-fibrinogen antibody-coated latex particles (LSI Medience Co., Tokyo, Japan) [8] .
Polymerase chain reaction (PCR) and DNA sequence analysis
Genomic DNA was extracted from white blood cells using a DNA Extraction WB Kit (Wako Pure Chemical Ltd, Osaka, Japan), according to the manufacturer's instructions.
To analyze all exons and exon-intron boundaries of fibrinogen genes, long-range PCR for FGA, FGB and FGG, and direct DNA sequencing for their purified PCR products were performed as described elsewhere [9] .
Purification of plasma fibrinogen
Fibrinogen was purified from citrated plasma obtained from the proposita, her mother, and a normal control subject by immunoaffinity chromatography using an IF-1monoclonal antibody (LSI Medience Co), and concentrations were determined as described elsewhere [9] . The purity of the proteins was determined by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) under reduced conditions (10% polyacrylamide gel). The characterization of the proteins was determined by SDS-PAGE under non-reduced conditions (5% polyacrylamide gel) followed by an immunoblot analysis with a rabbit anti human fibrinogen antibody (Dako, Carpinteria, CA, USA) and horse radish peroxidase-conjugated goat anti rabbit IgG antibody (Medical and Biological Laboratories Inc., Nagoya, Japan), or a rabbit anti-human albumin antibody (Dako) with the reacting species being visualized with the aid of an alkaline phosphatase-conjugated goat anti rabbit IgG antibody (EY Laboratories Inc., San Mateo, CA, USA) as described elsewhere [10] .
Preparation of mutant expression vectors and recombinant variant fibrinogens
Recombinant variant fibrinogens were prepared as described previously [11] . Briefly, the variant fibrinogen A chain expression vector, pMLP-A472S or -A442S, was altered from pMLP- at codon 472 TGT (Cys) to TCT (Ser) or 442 TGC (Cys) to TCC (Ser) by oligonucleotide-directed mutagenesis using the Quick Change II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) and the following primer pairs (the altered base is underlined); 5'-GAT GGT TCT GAC TCT CCC GAG 9 GCA ATG-3' (sense) and 5'-CAT TGC CTC GGG AGA GTC AGA ACC ATC-3' (antisense) for A472S, 5'-CCA CGC GTC GTT CAT CCT CTA AAA CCG TTA C-3' (sense) and 5'-GTA ACG GTT TTA GAG GAT GAA CGA CGC GTG G-3' (antisense) for A442S [11] . The resultant expression vector for A472S or A442S was co-transfected with the histidinol selection plasmid (pMSVhis) into Chinese hamster ovary (CHO) cells that expressed normal human fibrinogen B and  chains (B-CHO cells) as described elsewhere [11] . Ten colonies from each variant of fibrinogen-synthesizing CHO cells (A472S-or A442S-CHO cells) were selected at random and expanded to examine the synthesis of fibrinogen. Fibrinogen concentrations in culture media or cell lysates were determined by enzyme-linked immunosorbent assay (ELISA) as described previously [11] . Both recombinant fibrinogens, A472S and A442S, were purified from harvested serum-free medium by immunoaffinity chromatography and concentrations were determined as described elsewhere [9] .
Thrombin-catalyzed fibrin polymerization and thrombin clotting time
Polymerization was followed by measurements of changes in turbidity at 350 nm at ambient temperatures using the UVmini-1240 spectrophotometer (Shimadzu, Tokyo, Japan). Reactions were performed as described elsewhere [9] using 20 mM Bend, MA, USA). Three parameters: lag time, the maximum slope, and absorbance changes for 30 min (final OD), were obtained from the turbidity curves, as previously described [12] . Thrombin clotting time was also measured in duplicate as described elsewhere [8] .
Scanning electron microscopy (SEM)
To make fibrin clot, thrombin (10 L at 0.5 U/mL) was added to fibrinogen solution (40 L at 0.4 mg /mL). The SEM preparation was performed as described previously [9] .
Images were viewed on a JSM-6000F (Japan Electron Optics Laboratory Co. Ltd, Tokyo, Japan) and taken at 3,000x or 20,000x with a 5-kV accelerating voltage. Fiber diameters were measured using a vernier clipper on a 300% enlargement from a photograph of a 20,000x observation.
Clot lysis assay
The clot lysis assay was performed with plasmin or a mixture of the two-chain tissue type-plasminogen activator (t-PA) and plasminogen, as described previously [10] .
Briefly, 100 l of purified fibrinogen was polymerized in a micro-quartz cell with 10 U/mL of human -thrombin in polymerization buffer containing 1.0 mM CaCl2 and was then incubated for 2h at 37 °C. The final concentrations of fibrinogen and thrombin were 0.45 mg/mL and 1.0 U/mL, respectively. After the completion of polymerization, 100 l of plasmin (Chromogenix AB, Molngal, Sweden) (final concentration: plasmin:0.25 U/mL) or a mixture of t-PA (Genetech, South San Francisco,CA) and plasminogen (Roche Diagnostics GmbH, Mannheim, Germany) (final concentration: t-PA:1000 U/mL, and plasminogen: 1.0 U/mL) (t-PA/plasminogen mixture) was overlaid onto the clot, and clot lysis was monitored as a decrease in turbidity at 350 nm.
Three parameters: lag time [the time until maximum absorbance (as 100 %) decreased to 98 %], the maximum lysis rate (Lmax), and the 50 % lysis time (the period until maximum absorbance decreased to 50%), were obtained from the turbidity curves. All reactions were performed in duplicate.
Statistical analysis
The significance of differences between wild-type and variant fibrinogen was determined using a one-way ANOVA (analysis of variance) and Tukey-Kramer tests. A difference was considered significant when p <0.01.
Results

Coagulation screening tests and DNA sequence analysis
The results of the screening tests revealed that the proposita's plasma fibrinogen concentration determined by the thrombin time method and immunological method were low; 1.14 g/L and 1.33 g/L (normal range: 1.80 to 3.50 g/L), respectively. PT was A DNA sequence analysis for proposita and her mother revealed a novel heterozygous mutation of G>C FGA at exon 5 (at c.1472G>C; NCBI NM_021871), resulting in the substitution of Cys (TGT) for Ser (TCT) at the A472 residue (mature protein) or A491 (native protein) (AC472S). We designated this dysfibrinogenemia as Sumida, according to the place of residence of the proposita. To further analyze these additional bands, fibrinogen was run on 5% SDS-PAGE followed by an immunoblot analysis using with a rabbit anti-human fibrinogen antibody ( Figure 1C ) or rabbit anti-human albumin antibody ( Figure 1D ). Band-1 to band-3 were reacted with the anti-fibrinogen antibody and a faint fourth band between band-3 and HMW-fibrinogen could be visualized, which was indicated as band-4 ( Figure 1C ).
Characterization of purified plasma fibrinogen
Band-2 and band-4 were also reacted with the anti-albumin antibody ( Figure 1D ). We speculated that band-1 was the dimer of variant A472S-fibrinogen while both band-2 and band-4 were variant fibrinogen-albumin complexes. 
Scanning electron microscopy (SEM)
We observed fibrin clots under SEM in order to analyze differences in the ultrastructures of fibrin clots formed from fibrinogen of the normal control, Sumida, and Sumida's mother, (Figure 3 ). The density of clots formed from Sumida or Sumida's mother fibrinogen was higher than that of the normal control; however, the meshwork was curly, and fiber diameter was thinner than the normal control: 44.4 ± nm for Sumida (n = 30, p<0.01), 39.0 ±5.1 nm for Sumida's mother (n = 30, p<0.01), and 82.2 ± nm for the normal control (n = 30).
16
Clot lysis assay
Many previous studies have shown that albumin binding variant fibrinogens lead to thrombosis; therefore, we performed the clot lysis assay to clarify whether clots were resistant to plasmin degradation in vitro. Lysis curves for the 2 sets of experimental conditions using the proposita's plasma fibrinogen are shown in Figure 4 . The lag time, maximum slope (Lmax), and 50 % lysis time were measured on the clot lysis curve as 
Synthesis, secretion, and characterization of recombinant fibrinogens
Since the proposita's plasma fibrinogen antigenic concentration was 1.33 g/L, which was less than the normal range, we analyzed the fibrinogen synthesis and secretion of AC472S from CHO cell lines that expressed A472S-and A442S-fibrinogen as The culture medium to cell lysate ratios were 0.94 ± 0.12 for A472S-CHO cells and 1.05 ± 0.24 for A442S-CHO cells, which was higher than that of AN-CHO cells (no significance) ( Figure 5C ).
To confirm the purity of A472S-and A442S-fibrinogen purified from serum-free culture media, SDS-PAGE and Coomassie staining were performed under non-reducing or reducing conditions ( Figure 6 ). Under non-reducing conditions, intact fibrinogen, high molecular weight (HMW)-and low molecular weight (LMW)-fibrinogen [13] , were observed in AN-fibrinogen. Regarding A472S-and A442S-fibrinogen, the proportion of HMW-fibrinogen was lower than that of AN-fibrinogen, whereas the proportion of LMW-fibrinogen was increased while that of low molecular weight prime (LMW')-fibrinogen [13] was significantly elevated ( Figure 6A ). These results were confirmed under reducing conditions. The proportion of the A-chains of A472S-and A442S-fibrinogen was lower than that of AN-fibrinogen, namely the degradation of the A chains derived from variant fibrinogens was facilitated ( Figure 6B ). The degradation of the A chain derived from A442S-fibrinogen was faster than that from A472S-fibrinogen.
Discussion
We herein described a novel case of dysfibrinogenemia with a heterozygous missense mutation in FGA at exon 5, which resulted in an AC472S substitution in the C-domain and was designated as Sumida. A472C is an important residue for the formation of a disulfide bond between A442C. Sumida's purified plasma fibrinogen showed the presence of some albumin-binding variant fibrinogens and a dimer of a 19 variant fibrinogen. Although Sumida's fibrinogen concentration ratio of the thrombin time method to the antigenic method was 0.857 and notably higher than those observed for other -chain aberrant dysfibrinogenemias (0.05 -0.50) reported previously [8, 14] , thrombin-catalyzed fibrin polymerization using Sumida's purified plasma fibrinogen was markedly impaired with a less steep maximum slope and smaller final OD than those of the normal control.
We suspected that this patient may have hypodysfibrinogenemia because fibrinogen concentrations determined by both the functional and antigenic methods were lower than the lower level of reference intervals, whereas the fibrinogen concentration ratio was higher, as described above. To clarify the synthesis and secretion of fibrinogen by the proposita, we produced CHO cell lines that generated the recombinant variant fibrinogen, A472S or A442S, both of which are counterparts of the intra-chain disulfide bond in the A-chain. The culture medium to cell lysate ratios derived from both variant cell lines were unaffected while those of the A442S cell lines were higher than the normal control. These results were consistent with previous findings in COS-1 cells [15] . Namely, the destruction of the A442C-472C disulfide bond did not prevent the synthesis and secretion of fibrinogen. However, SDS-PAGE and the western blot analysis demonstrated that the degradation of the purified recombinant variant 20 fibrinogen from the culture media, A472S or A442S fibrinogen, was faster than that of the normal control; degradation of the A-chain was particularly enhanced. However, the same phenomenon was not observed for purified plasma fibrinogen from the proposita (Fig 1B) . Therefore, we speculated that the variant A chain in Sumida's plasma fibrinogen was degraded faster than that of the normal control, and the B and  chains of the A chain-degraded variant fibrinogen also facilitated degradation by some plasma proteases, leading to a less constitutional proportion of variant to normal fibrinogen, which ultimately resulted in a higher fibrinogen concentration ratio of the thrombin time method to the antigenic method. Some of the cases of C-domain-affected dysfibrinogenemias [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] , including Lincoln (variant fibrinogen; 23%) [29] , Caracas I (10 -20%) [27] , and Perth (12%) [31] , were reported similarly to Sumida ( Table 1 ).
The fibrin polymerization curve for Sumida's purified plasma fibrinogen showed markedly impaired lateral aggregation of protofibrils. The C-domain has been shown to prompt the lateral aggregation of protofibrils during fibrin polymerization [6] .
Therefore, the substitution of C to S at the A472 residue leads to the destruction of the disulfide bond, resulting in marked conformational changes in the C-domain.
Furthermore, our results demonstrated that disulfide bond-free A442C bound to the (Table 1 ) [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Six out of 13 families with the albumin-binding variant fibrinogen, affected the lateral aggregation of protofibrils, and thin fibrin fiber diameters manifested thrombotic complications (Table 1) , whereas 4 out of 13 families manifested bleeding complications (Table 1 ).
Sumida's fibrinogen also affected the lateral aggregation of protofibrils and caused a thin fibrin fiber diameter. Therefore, we performed a clot lysis assay by the procedure involving plasmin or a mixture of t-PA and plasminogen being overlaid onto the clot.
Sumida's clot lysis was similar to that of the normal control under both conditions;
however, it is difficult to evaluate whether Sumida's clot structure was resistant to plasmin digestion and Sumida's fibrin activated plasminogen mediated by t-PA. Sumida's fibrinogen is a novel heterozygous dysfunctional fibrinogen characterized by the substitution of Ser for A472Cys, the existence of additional disulfide-bonded molecules, impairment of lateral aggregation of protofibrils, and formation of thin fiber fibrin clots. Although the proposita and her affected mother had no history of bleeding and a thrombotic tendency, both must be cautious not only of bleeding, but also thrombotic complications because some similar variants located in the C-domain exhibited impairments in t-PA-mediated plasminogen activation. 
Conflicts of Interest Statement
The authors state that they have no conflicts of interest. After the completion of fibrin polymerization, either plasmin (A) or a mixture of t-PA and plasminogen (B) was overlaid onto the clots as described in Materials and methods.
Clot lysis was performed in triplicate and each representative curve is shown as the normal () and Sumida (). 
